The effects of dapagliflozin on cardio‐renal risk factors in patients with type 2 diabetes with or without renin‐angiotensin system inhibitor treatment: a post hoc analysis

AIMS: Renin‐angiotensin system inhibitors (RASi) are the most effective treatments for diabetic kidney disease but significant residual renal risk remains, possibly because of other mechanisms of kidney disease progression unrelated to RAS that may be present. Sodium‐glucose co‐transporter‐2 inhibit...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Diabetes Obes Metab
Main Authors: Scholtes, Rosalie A., van Raalte, Daniël H., Correa‐Rotter, Ricardo, Toto, Robert D., Heerspink, Hiddo J. L., Cain, Valerie, Sjöström, C. David, Sartipy, Peter, Stefánsson, Bergur V.
Format: Artigo
Jezik:Inglês
Izdano: Blackwell Publishing Ltd 2019
Teme:
Original Articles
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7078964/
https://ncbi.nlm.nih.gov/pubmed/31742881
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13923
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki